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Abstract 
The rapid advance of gene sequencing technologies has produced an unprecedented rate of discovery 
for genome variation in humans. A growing numbered of authoritative clinical repositories archive gene 
variants and disease phenotype, yet there are currently many more gene variants that lack clear 
annotation or disease association. To date, there has been very limited coverage of gene-specific 
predictors in the literature. Here we present the evaluation of "gene-specific" predictor models based 
on a Na"ive Bayesian classifier for 20 gene-disease data sets, containing 3,986 variants with clinically 
characterized patient conditions. Utility of gene-specific prediction is then compared "all-gene" 
generalized prediction and also to existing popular predictors. Gene-specific computational prediction 
models derived from clinically curated gene variant disease data sets often outperform established 

























































f Vle Ameri~an Medicjtl-.lflfp rrnattcs AS~Qcia~on 1 R -t 
unlverslty 01 Ulan J.nSlllUllona epoSl ory 
Author Manuscript Crockett et al 
Background and Significance 
Personalized medicine implies that all relevant clinical information is available on demand for effective 
patient treatment. Proper interpretation of gene test results is a key component in customizing patient 
therapy. Efforts such as the Human Variome Project, 1000 Genomes and NCB I Genetic Testing Registry 
highlight a growing interest in annotation and clinical interpretation of gene variants in human 
disease.{1-3) As genetic information is incorporated into the electronic medical record, new decision 
support approaches are needed to provide clinicians with a preferred course of treatment.(4) For 
decision support rules to add value, the clinical relevance of laboratory information must be well 
understood.{S, 6) 
Furthermore, with rapidly evolving technologies such as SNP chip genome wide association studies and 
next-generation sequencing, genomic analysis is trending faster and cheaper and yielding much larger 
data sets. As such, gene variants are being discovered at an almost astronomical pace, with one recent 
report finding an average of 3 million variants per personal genome.(7) More importantly, for genomic 
variation to be of real clinical utility, laboratory interpretation and disease association must be well 
understood for each new gene variant found. (8, 9) 
Unfortunately, an increasingly apparent gap exists between rapidly growing collections of genetic 
variation and practical clinical implementation. Although collections of human genome variation have 
been underway for years, authoritative repositories of gene variants with clear association to disease 
phenotype are only now beginning to emerge.{10-14) This is in contrast to existing collections of 
genome-wide mutations such as dbSNP{lS) or OMIM(16) that are not curated using consistent, 
systematic or transparent methods. Focusing computer predictive algorithms on authoritative and 
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Prediction algorithms for computing mutation severity have been used for many years.(17-20) Despite 
their use in laboratories, they do not have sufficient accuracy to predict disease phenotype to the 
degree necessary to be clinically applicable. This prompts opportunities to explore the application of 
advanced informatics approaches to this problem.(21-23) This study expands the recently reported 
Primary Sequence Amino Acid Properties (PSAAP) algorithm (24, 25), which uses a gene-specific 
classification approach utilizing amino acid physicochemical properties of the primary amino acid 
sequence to predict pathogenicity of novel and/or uncertain gene variants. To date, gene-specific 
approaches have been applied only to the RET proto-oncogene and hypertrophic cardiomyopathy.(25, 
26) 
To evaluate the generalizability of our gene-specific PSAAP algorithm, we extend its use to a set of 20 
genes with clinically curated disease variants (Table 1). The analyses also compare the effectiveness of 
generic gene versus gene specific approaches using a minimum (non-redundant) set of amino acid 
properties to describe exonic non-synonymous variants coupled with evaluation of overlap and/or 
trends of biochemical properties of mutation. 
Methods 
Gene variant data relating well-characterized patient condition to genotype (genotype-phenotype) were 
assembled from multiple sources including: cystic fibrosis mutation database curated by Ruslan Dorfman 
(Hospital for Sick Children, Toronto}(27); BioPKU database curated by Nenad Blau (University Children's' 
Hospital, Zurich)(28); neurofibromatosis type 1 database curated by Ophelia Maertens (Center for 
Medical Genetics, University Hospital, Ghent) and Collagen, type IV, alpha 5 (COL4A5) Mental 
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hosted by Leiden Open Source Variation Database (LOVD)(29-31); biotinidase (BTO) curated by Barry 
Wolf (Medical Genetics, Henry Ford Hospital, Detroit)(32); aryl hydrocarbon receptor interacting protein 
(AlP) curated by Rodrigo Toledo (Endocrine Genetics Unit, University of Sao Paulo Medical School) 
(personal communication); Disease Databases hosted by Department of Pathology, University of Utah 
School of Medicine(33) and genetic testing results archived at ARUP Laboratories (Salt Lake City) . The 
clinically curated gene-disease data sets (n=20) containing some 3986 curated variants are summarized 
in Table 1. 
This 20 gene collection contained 1639 exonic non-synonymous SNP's (nsSNP) with known outcomes of 
benign (n=607) and pathogenic (n=1032). The gene variants were characterized using physicochemical 
properties of the substituted amino acid as recently reported .(24, 25) Briefly, gene-specific clinically 
curated missense variants (nsSNP's) were characterized using a Na·ive Bayes classification scheme of 
primary amino acid sequence only and delta differences in physical, chemical, conformational, or 
energetic properties between the amino acid present in the wild type and the variant. Descriptors were 
attributes derived from 544 amino acid properties archived in AAindex v9.4.(34) AAindex is a database 
of numerical indices representing various physicochemical and biochemical properties of amino acids. 
For each gene variant, vectors of delta values for each biochemical property of the substituted amino 
acid were calculated and the resulting mutation described by an array of variables, corresponding to the 
absolute value of the difference between wild type and mutant - as trained in a gene-specific setting. 
Based on curated clinical outcomes of benign or pathogenic, the minimum (non-redundant) set of amino 
acid properties needed to describe pathogenicity of gene variants was investigated using various 
attribute selection methods such as correlation-based feature subset selection, SVM-RFE and Relief-F 
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this analysis. The best performing correlation-based feature subset selection and Na"ive Bayes 
classification was implemented using the Weka software package.(35) 
For each of the 20 genes, random selection was used to build a 2/3 training and a 1/3 test sets with 
known class labels (benign, pathogenic) . Training and test sets were to keep the original ratio of benign 
and pathogenic constant, but without regard to functional motif or protein location. Next, based on 
curated clinical classification of benign or pathogenic, algorithm training and pathogenicity prediction 
was performed gene-by-gene. Gene-specific models were also tested for prediction of other gene-
disease outcomes, by using the training set of one gene and a test set from a second gene. In a similar 
fashion, an "all-gene" model was constructed using all the available training sets. This "all-gene" model 
was then tested by making gene-by-gene predictions. Due to a low number of nsSNP exonic 
substitution variants, five genes (MECP2, MSH2, MSH6, PLODl and SPINK1) were only included in the all-
gene training set, and not used for gene-specific training. Algorithm performance was evaluated using 
each gene test set, with sensitivity (true positive rate), specificity (true negative rate), and positive 
predictive value (PPV or precision) calculated for each classifier algorithm and gene-specific and all-gene 
permutations. 
Well established prediction tools such as PolyPhen (18) and SIFT (17) are primarily based on multiple 
alignment and amino acid substitution penalties have been available for many years. More recently, 
MutPred (20) which calculates probability of deleterious mutations by disrupted molecular mechanism. 
Additionally, PMut (19) is neural net based and trained on human mutations. (A more detailed 
description of each prediction algorithm is given in Supplementary Data .) Lastly, gene-specific algorithm 
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PMUT(19) and MutPred(20) . Comparison of established prediction tools with gene-specific trained 
algorithms may increase our understanding of predicting mutation status. 
For all genes, the full length protein isoform was used for this study. Splice variants were not 
considered. All gene variants were mapped to their reference amino acid sequence from UniProtKB 
(http://www.uniprot.org). Protein reference sequences are summarized in Supplementary Table 1. 
Results and Discussion 
Overall, the performance of the gene-specific trained algorithm was significantly better (8% to 13%) 
than the "all-gene" model, with p values of 0.00001 (sensitivity), 0.00113 (specificity) and 0.00012 (PPV) 
as shown in Figure 1. For the genes evaluated, the PPV of our gene-specific PSAAP algorithm averaged 
89% (82% to 94%). This was on average 11% higher than the "all-gene" model where PPV ranged from 
62% to 86%. The one exception was SLC22A5, where PPV remained constant. Sensitivity averaged 13% 
higher than the "all-gene" model, except for SPREDl which was 6% decreased. Specificity was also 
generally improved (9% average) for all but PMS2 (no increase) and NFl , which was 5% decreased. 
For the genes studied here, the PSAAP gene-specific prediction performs well. PPV values are displayed 
in Supplementary Table 2. The self against self is plotted on the diagonal in blue with ppv>80 bolded . 
Other gene predictor performance with PPV above 80 is shaded in orange. Interestingly, gene-specific 
prediction models do not seem to generalize well - even across similar protein functional families. For 
instance, Supplementary Table 2 shows that the RET kinase trained model (94% PPV) performed lower 
for the ACVRLl kinase (84% PPV) while the ACVRLl trained predictor (88% PPV) only predicted RET with 
80% PPV. Additionally, the carboxylase enzyme BTD (91% PPV) only predicted the hydroxylase PAH 
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59% PPV. It is notable however, that 3 out of 15 genes (SPRED1, NFl and GAL T) yielded comparable 
numbers for predicting disease association across other genes. 
The improved performance of gene-specific algorithms may be explained in part by an important 
observation that biochemical and/or structural characteristics of mutation specific to one disease may 
be lost or diluted when combined with large genome-wide data sets for algorithm development. This 
can be illustrated by plotting non-synonymous variants specific to a gene-disease condition as compared 
to random amino acid substitutions. When 1000 random amino acid changes were plotted 
(Supplementary Figure lA), a wide distribution evenly covers the entire range of possible substitutions. 
In contrast, when 1000 pathogenic mutations are graphed, characteristic trends of specific residues and 
frequency of substitution are readily seen (Supplementary Figure IB) . More importantly, disease-
specific examples of this concept are shown in Figure 2. In the RET proto-oncogene (associated with 
medullary thyroid cancers), some 79% of all pathogenic changes were found to involve cysteine (C) to 
some other residue (X) as displayed in Figure 2A. In the COL4A5 gene (associated with Alport 
syndrome), 84% of pathogenic changes involve glycine (G) to other residues (X) as shown in Figure 2B. 
To confirm this trend, further experiments should be performed as additional curated gene-disease 
collections become available. 
Although the majority of the PSAAP models did not perform as well for predicting pathogenicity in other 
genes-diseases, most still outperformed established algorithms. As shown in Table 2, a majority of 
genes (13 out of 15) analyzed using the gene-specific PSAAP trained algorithm had improved PPV as 
compared to other algorithms, with the overall PPV increasing 8.8% to 22.0%. For example, the PSAAP 
model specific for SPREDl (93% PPV as seen in Table 2), when analyzed using established prediction 
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for RET kinase (94% PPV) underperformed for the ACVRLl kinase (84% PPV), however, both still 
outperformed established algorithms, where on-line predictions for ACVRLl only ranged from 57% to 
81% PPV. Two exceptions to this trend were GALT and SMAD, in which MutPred and/or PMut scored 
slightly higher as shown bolded/underlined in Table 2. 
It is important to note that the all-gene trained Bayes predictor also compares favorably to established 
algorithms, with the average, minimum and maximum PPV for each predictor also summarized in Table 
2. For instance, although the gene-specific trained PSAAP model yielded the best PPV, the all-gene 
trained model outscores 3 of 4 established predictors, with MutPred being the exception. This 
observation may highlight the importance of authoritative variant data and amino acid physicochemical 
properties being used to develop/train algorithms. It also demonstrates that primary acid sequence 
only, when coupled with amino acid properties, can be successfully used to develop predictor 
algorithms. 
Finally, a minimum attribute set of amino acid properties seems specific to each gene-disease, with 
overlap found among different genes using three feature selection methods ranging from 11% to 80% as 
summarized in Supplementary Table 3. Representative examples are shown in Figure 3. Interestingly, 
the gene models with more shared amino acid attributes (GALT, 80%; NFl, 62%; SPRED1, 60%) also had 
the best generalizability. Of note, both SMAD4 and GALT did well using the established on-line 
prediction tools, where SMAD4 also had 58% overlap. Without considering the above mentioned 4 
genes, the overlap ranged from only 11% to 37%. Overlap for the all gene data set follows this same 
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The number of authoritative disease and locus specific gene variant collections in use for clinical 
diagnostics is rapidly growing. These clinically-curated gene variant data sets, with reliable genotype-
phenotype association, can readily be utilized for training and test set performance of machine 
classifiers. The generalizability of classification rules across multiple genes and diseases may be 
strengthened as the number of curated disease variants continues to increase, although our analysis 
suggests that gene-specific approaches will, with few exceptions, outperform generic approaches. 
Nonetheless, the recognition that the proposed classifier outperforms existing tools is important, given 
that it will take time for disease-specific curated genotype-phenotype databases to be developed and 
for some ultra-rare diseases such databases may never be realistic . 
For machine learning classifiers, amino acid attributes characteristic of substitution mutations for a 
given disease may be lost or diluted when combined with multiple genes and diseases. A key 
distinguishing feature of this gene-specific classifier methodology is that algorithms are trained explicitly 
to curated monogenic disease outcomes. While this methodology is complementary to established 
generalized prediction tools, algorithms should take advantage of authoritative (clinically-curated) gene 
variant collections where they exist. This is especially important when pathologic variants exhibit 
characteristic trends or properties specific to a given disease. 
This study included only gene variant collections with clearly documented disease association and 
known to the authors - and represents the largest collections to-date of clinically curated gene-disease 
results as used for diagnostic and gene test reporting purposes. Although correlation of genotype-
phenotype offers therapeutic options that would otherwise remain hidden and may lead to disease 
specific mutation-guided management strategies, appropriate caution is justified when clinicians are 
asked to trust computational outcomes for determining patient care.(36) Continued interaction 
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between clinicians and laboratorians to refine mutation-specific clinical classification is imperative to 
optimal patient care.{5, 6} 
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Figure Legends 
Figure 1. Performance of the gene-specific PSAAP algorithm as compared to all-gene algorithm plotted 
to show A) sensitivity, B) specificity and C) positive predictive value (PPV) . Significance was calculated 
using a 2 tailed paired t-test. 
Figure 2. Disease specificity of pathogenic mutations demonstrated by plotting A) the RET proto-
oncogene variants where 79% of pathogenic changes are cysteine [C] to another residue [X] and B) 
COL4A5 where 84% pathogenic changes are glycine [G] to another residue [X] again showing 
characteristic trends of specific residues and frequency of substitution that may be lost when diluting 
gene-specific data into genome wide computational methods. 
Figure 3. Venn diagram showing overlap of amino acid properties to characterize benign and 
pathogenic gene variants using three feature selection methods (CfsSubset, Relief-F, SVM-RFE) . Overlap 
for A) RET with only 14% shared attributes, B) GALT with a much higher 80% overlap and C) the all-gene 
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Table 1. Summary of c1inically-curated gene variant data sets (n=20) with known disease association. 
Gene Symbol Gene Name Curated Exonic 
Biological Function Disease Association Variants nsSNPs 
ACVRLl activin A receptor type II-like 1 332 192 
activin receptor activity, type 1 hereditary hemorrhagic telangiectasia 
AlP aryl hydrocarbon receptor interacting protein 102 84 
transcription coactivator activity familial pituitary adenoma 
BTD biotinidase 155 105 
biotin carboxylase activity biotinidase deficiency 
CFTR cystic fibrosis transmembrane conductance regulator 252 121 
chloride channel regulator activity cystic fibrosis 
COL4A5 collagen, type IV, alpha 5 600 266 
extracellular matrix structural constituent X-linked Alport syndrome (hereditary nephritis) 
ENG endoglin 397 124 
TGF ~ receptor activity hereditary hemorrhagic telangiectasia 
GALT galactose-1-phosphate uridylyltransferase 247 168 
uridylyltransferase activity galactosemia 
GJB2 gap junction protein, beta 2 (connexin 26) 61 43 
gap junction channel activity hereditary sensorineural hearing loss 
MECP2 methyl CpG binding protein 2 26 14 
transcription co-repressor activity Rett syndrome 
MSH2 mutS homolog 2 89 8 
guanine/thymine mispair binding hereditary nonpolyposis colonrectal cancer 
MSH6 mutS homolog 6 34 10 
guanine/thymine mispair binding hereditary nonpolyposis colonrectal cancer 
NFl neurofibromin 1 125 121 
Ras GTPase activator activity neurofibromatosis type 1 
PAH phenylalanine hydroxylase 730 126 
phenylalanine catabolism phenylketonuria (PKU) 
PLODl procollagen-Iysine 1, 2-oxoglutarate 5-dioxygenase 1 34 12 
procollagen-Iysine-dioxygenase activity Ehlers-Danlos syndrome type VI 
PMS2 postmeiotic segregation increased 2 348 45 
mismatched DNA binding hereditary nonpolyposis colorectal cancer 
RET ret proto-oncogene 146 97 
transmembrane receptor kinase activity multiple endocrine neoplasia, medullary thyroid carcinoma 
SLC22A5 solute carrier family 22, member 5 95 57 
carnitine transporter activity primary carnitine deficiency 
SMAD4 SMAD family member 4 86 23 
transcription activator activity juvenile polyposis syndrome, pancreatic cancer 
SPINKl serine peptidase inhibitor, Kazal type 1 73 5 
endopeptidase inhibitor activity hereditary pancreatitis 
SPREDl sprouty-related, EVH1 domain containing 1 54 18 
inactivation of MAPK activity Legius syndrome (neurofibromatosis type-like syndrome) 
16 
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a Primary Sequence Amino Acid Properties (PSAAP) algorithm, gene-specific trained . 
b Primary Sequence Amino Acid Properties (PSAAP) algorithm, all-gene (n=20) tra ined. 
C Analyzed with default settings at http://sift.jcvLorg. 
d Analyzed with default settings at http://genetics.bwh.harvard.edu/pph. 
e Analyzed with default settings at http://mmb.pcb.ub.es/PMut. 
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Supplementary Table 1. Reference amino acid sequence from UniProtKBa• 
Gene symbol UniProt # Protein name AA length Date accessed 
ACVRLl P37023 ACVLl_HUMAN 503 December 6,2010 
AlP 000170 AlP _HUMAN 330 January 5, 2011 
BTO P43251 BTD_HUMAN 543 December 6, 2010 
CFTR P13569 CFTR_HUMAN 1480 December 6, 2010 
COL4AS P29400 C04A5_HUMAN 1685 December 7, 2010 
ENG P17813 EGLN_HUMAN 658 December 7, 2010 
GALT P07902 GALT_HUMAN 379 December 7,2010 
GJB2 P29033 CXB2_HUMAN 226 December 7, 2010 
MECP2 P51608 MECP2_HUMAN 486 December 7, 2010 
MsH2 P43246 MSH2_HUMAN 934 December 8, 2010 
MsH6 P52701 MSH6_HUMAN 1360 December 8, 2010 
NFl P21359 NFl_HUMAN 2839 January 5, 2011 
PAH P00439 PH4H_HUMAN 452 January 6, 2011 
PLOOl Q02809 PLOD1_HUMAN 727 December 9, 2010 
PMs2 P54278 PMS2_HUMAN 862 December 9,2010 
RET P07949 RET_HUMAN 1114 December 9,2010 
sLC22AS 076082 S22A5_HUMAN 557 December 9, 2010 
SMA 04 Q13485 SMAD4_HUMAN 552 January 7, 2011 
sPINKl P00995 ISK1_HUMAN 79 December 9, 2010 
sPREOl Q7Z699 SPREl HUMAN 444 December 9,2010 
a http://www.uniprot.org. 
http://mc.manuscriptcentral.com/jamia 
Journal ( f 'l1 Amerif an ~edicfltJff:r~t~s Aff¥Cit~On 1 R . t Page 2 ) 1l!J u 'V-, "~U lOll ',;m ']) ill". n1Ve S1 y 0 a ns U 10na epOS1 ory 




3 Supplementary Table 2. PPV of gene-specific algorithms to predict pathogenicity in other genes. 4 
5 
6 ACVR LI AlP BTD CFTR COL4A5 ENG GALT GJB2 NFl PAH PMS2 RET SLC22A5 SMAD4 SPR EDl 
7 
8 e ~E ACVR LI 88 83 74 70 84 77 79 79 85 74 76 80 81 72 78 
1 ~ AlP 72 91 62 62 69 59 66 55 68 57 65 63 62 58 62 
1 ~ 
1~ BTD 77 79 91 77 85 73 82 81 85 76 70 70 71 81 85 
1 ~ 
13"t 
1 ~ CFTR 53 62 56 90 56 54 59 55 51 54 47 60 53 57 61 
1;b 
1 ~ COL4A5 47 58 62 51 88 83 55 61 52 57 46 56 57 56 50 
1 ~ 203· ENG 48 47 62 57 84 92 49 55 51 56 50 60 54 60 61 
rt 21 
22 GALT 83 82 85 80 77 74 86 77 80 81 85 80 81 77 84 
23 
24 
25 GJB2 67 56 73 54 56 70 73 87 55 66 69 64 62 56 71 
26 
27 NFl 90 76 84 75 90 89 75 79 89 83 75 73 78 81 84 
28 
29 PAH 62 74 59 55 63 58 64 60 82 89 58 71 65 60 59 
30 
31 PMS2 66 62 63 61 61 70 55 69 62 71 88 66 70 63 56 
32 
33 
34 RET 84 69 62 42 64 57 46 72 66 72 45 94 49 68 59 
35 
36 SLC22A5 74 66 63 73 72 71 69 68 73 70 68 72 82 71 81 
37 
38 SMAD4 49 53 65 61 49 64 47 53 67 67 56 52 64 84 67 
39 
40 
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8 e CfsSubset Relief-F SVM-RFE Overlap ~E ACVRLl 7 39 49 7 
1 ~ AlP 90 29 117 25 1 ~ 
1~ BTO 41 20 39 8 
1 ~ CFTR 19 161 139 12 13"t 
1 ~ COL4A5 63 65 88 21 
1;b 
1 ~ ENG 13 82 59 9 
1 ~ 203· GALT 46 40 45 35 
rt 21 GJB2 11 37 145 11 
22 
23 NFl 28 20 39 18 
24 PAH 29 73 129 24 
25 
26 PMs2 13 58 107 11 
27 RET 87 56 47 9 28 
29 sLC22A5 76 96 87 13 
30 SMA 04 63 65 88 42 31 
32 sPREOl 59 44 31 27 
33 
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Supplementary Figure 1. Specificity of pathogenic mutations demonstrated by plotting A) simulated 
random amino acid substitutions (n=1000) showing a wide distribution that evenly covers the entire 
range of possible substitutions and B) known pathogenic mutations (n=1000) showing characteristic 
trends of specific residues and frequency of substitution. 
http://mc.manuscriptcentral.com/jamia 
